Acute Administration of Corticoids: A New and Peculiar Stimulus of Growth Hormone Secretion in Man*
- 1 January 1990
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (1) , 234-237
- https://doi.org/10.1210/jcem-70-1-234
Abstract
It is widely accepted that chronic administration of corticoids in man inhibits the GH response to all of the stimuli tested so far. To study the action of corticoids administered acutely, several dexamethasone challenge tests were performed, after which GH levels were measured for 7 h. In eight volunteers, administration of 4 mg dexamethasone (Dex), iv, induced a clear-cut GH release compared with saline administration. The secretion followed an unusual pattern; basal GH levels (1.5 .+-. 0.1 .mu.g/L) started rising 2 h after Dex injection, reaching a peak of 17.5 .+-. 4.4 .mu.g/L after 3 or 3.5 h. Peak levels were maintained until 5 h post-Dex and decreased thereafter. Similar data were otained when Dex was administered to five volunteers at the dose of 8 mg, orally, with a 30-min delay of the GH peak (19.6 .+-. 7.9 .mu.g/L). To study whether there was a cholinergic input responsible for the Dex action, another group of eight volunteers underwent three Dex tests (4 mg, iv) on three occasins, followed 90 min later by the administration of placebo (control), atropine (0.5 mg, iv), or pyridostigmine (120 mg, orally). The Dex-induced GH peak (20.8 .+-. 5.2 .mu.g/L) was not significantly increased by pyridostigmine (cholinergic agonist) treatment (24.2 .+-. 4.0 .mu.g/mL). The blockade of muscarinic receptors by atropine induced a delay in the Dex-induced secretory peak, which appeared at 5 h. However, the Dex-atropine GH peak (14.9 .+-. 4.1 .mu.g/L) was not different from the Dex-placebo one. In conclusion, Dex alone is able to induce a clear-cut GH secretion in man. The stimulus followed a peculiar time pattern, with peaks levels attained 3 h after either iv or oral administration.This publication has 11 references indexed in Scilit:
- Cholinergic Receptor Activation by Pyridostigmine Restores Growth Hormone (GH) Responsiveness to GH Releasing Hormone Administration in Obese Subjects: Evidence for Hypothalamic Somatostatinergic Participation in the Blunted GH Release of Obesity*Journal of Clinical Endocrinology & Metabolism, 1989
- Depending on the Time of Administration, Dexamethasone Potentiates or Blocks Growth Hormone-Releasing Hormone-Induced Growth Hormone Release in ManNeuroendocrinology, 1988
- Glucocorticoid Control of Rat Growth Hormone Gene Expression: Effect on Cytoplasmic Messenger Ribonucleic Acid Production and DegradationMolecular Endocrinology, 1987
- GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRHClinical Endocrinology, 1987
- Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatinJournal of Endocrinology, 1986
- Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in manActa Endocrinologica, 1986
- ATROPINE SELECTIVELY BLOCKS GHRH‐INDUCED GH SECRETION WITHOUT ALTERING LH, FSH, TSH, PRL AND ACTH/CORTISOL SECRETION ELICITED BY THEIR SPECIFIC HYPOTHALAMIC RELEASING FACTORSClinical Endocrinology, 1986
- Effect of Dexamethasone on Growth Hormone (GH) Response to Growth Hormone Releasing Hormone in Acromegaly*Journal of Clinical Endocrinology & Metabolism, 1985
- Regulation of growth hormone messenger RNA by thyroid and glucocorticoid hormones.Proceedings of the National Academy of Sciences, 1977
- Human Growth HormoneNew England Journal of Medicine, 1964